Outlook Therapeutics OTLKW 深 沪
等待开盘 09-02 09:30:00 美东时间
0.03
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.03
- 总市值 8.75万
- 52周最高 1.27
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.01
- 委 比 0.00%
- 总股本 291.70万
- 历史最高 3.49
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.01
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Downgrades Outlook Therapeutics to Neutral, Announces $1 Price Target
HC Wainwright & Co. analyst Douglas Tsao downgrades Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral and announces $1 price target.
08-29 20:47
FDA Declines Outlook Therapeutics' Wet AMD Drug Application In Present Form
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM
08-28 18:33
Why MongoDB Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
Shares of MongoDB, Inc. (NASDAQ:MDB) rose sharply in pre-market trading after t...
08-27 18:05
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-18 19:50
Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies
Outlook Therapeutics (OTLK) has disclosed a new risk, in the Capital Markets ca...
08-16 14:00
Chardan Capital Maintains Neutral on Outlook Therapeutics, Maintains $3 Price Target
Chardan Capital analyst Daniil Gataulin maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $3 price target.
08-15 20:07
Outlook Therapeutics Q3 Adj. EPS $(0.44) Misses $(0.39) Estimate, Sales $1.505M Miss $1.663M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.39) by 11.96 percent. This is a 46.99 percent increase over losses of $(0.83) per share
08-14 20:23
Outlook Therapeutics announces CEO appointment
Outlook Therapeutics (NASDAQ:OTLK) has named Bob Jahr as chief executive officer and a member of its board. Jahr succeeds interim CEO Lawrence A. Kenyon, who will continue as chief financial officer a...
07-01 20:22
Outlook Therapeutics Appoints Bob Jahr As CEO
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographiesCareer focused on driving business growth and developing an integrated
07-01 20:12
Rubrik To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
06-06 20:51
